EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission

Katie A Dunleavy iD, Chad R Rypstra, Irene Busciglio, Deborah Eckert, Michael Ryks, Ellie Omerdic, Victor G Chedid, Laura E Raffals, Michael Camilleri iD

Inflammatory Bowel Diseases · 01.09.2025 · 31 (9) · 2511-2520

DOI: 10.1093/ibd/izaf043 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 11.03.2025. Verfasst von Katie A Dunleavy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Intestinal Mucosa, Crohn Disease, Colitis, Ulcerative, Intestine, Small. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Department of Laboratory Medicine and Pathology, Mayo Clinic, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Inflammatory bowel disease (IBD) is associated with altered mucus and increased intestinal permeability (IP). Prior reports on permeability in IBD typically used lactulose-to-mannitol ratio (LMR). Food contamination with 12C-mannitol is a significant potential confounder in IP assessment. We aimed to compare small intestinal (SI) and colonic (COL) permeability in IBD, both active (ACT) and in remission (REM), to normal healthy volunteers (NHV).

Methods

Inflammatory bowel disease activity was based on Simple Endoscopic Score for Crohn’s Disease (SES-CD) and Mayo endoscopy score for ulcerative colitis (UC). We performed 24-hour IP test using 100 mg 13C-mannitol and 1000 mg lactulose with urine collected during 0-2, 2-8, and 8-24 hours. The primary endpoint was mg excretion of 13C-mannitol and lactulose during 2-24 hours reflecting SI and COL permeability.

Results

Among 17 CD patients, 7 were ACT (SES-CD >6), and 10 REM (SES-CD 0-2). Among 20 UC patients, 10 had ACT (Mayo score 2-3), and 10 REM (Mayo score 0-1). Urinary excretions over 2-24 hours were higher for IBD than NHV: 13C-mannitol (13.8 [IQR 8.8, 18.7] NHV; 18.4 [15.6, 29.9] REM; 19.7 [13.8, 23.6] ACT, P = .003) and lactulose (1.8 [1.3, 3.1] NHV; 3.6 [2.0, 5.0] REM; 3.5 [2.0, 6.6] ACT, P = .006). There was no difference between ACT and REM for any timed urine collection. LMR at 2-24 hours (or 2-8 and 8-24 hours) were not statistically significant between the 3 groups (0.014 [0.010, 0.021] NHV; 0.016 [0.010, 0.023] REM; 0.016 [0.012, 0.038] ACT, P = .237).

Conclusions

Intestinal permeability is increased in IBD using validated in vivo assay relative to NHV; increased IP in IBD persists during remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal MucosaCrohn DiseaseColitis, UlcerativeIntestine, SmallColonInflammatory Bowel DiseasesHumansMaleFemaleAdultPermeabilityLactuloseMannitolMiddle AgedRemission InductionCase-Control StudiesYoung AdultIntestinal Barrier Function

Stichwörter der Autor:innen

IBDbarrierlactulosemannitol

Substanzen

LactuloseMannitol

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Katie A Dunleavy, Michael Camilleri

Förderung

  • NIH HHS
  • Department of Laboratory Medicine and Pathology, Mayo Clinic
  • NIDDK NIH HHS
  • National Institutes of Health

Zitieren

APA

Dunleavy, K. A., Rypstra, C. R., Busciglio, I., Eckert, D., Ryks, M., Omerdic, E., Chedid, V. G., Raffals, L. E., & Camilleri, M. (2025). Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission. Inflammatory Bowel Diseases, 31(9), 2511-2520. https://doi.org/10.1093/ibd/izaf043

Vancouver

Dunleavy KA, Rypstra CR, Busciglio I, Eckert D, Ryks M, Omerdic E, et al. Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission. Inflammatory Bowel Diseases. 2025;31(9):2511-2520. doi:10.1093/ibd/izaf043

BibTeX
@article{Dunleavy2025,
  author = {Dunleavy, Katie A and Rypstra, Chad R and Busciglio, Irene and Eckert, Deborah and Ryks, Michael and Omerdic, Ellie and Chedid, Victor G and Raffals, Laura E and Camilleri, Michael},
  title = {Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {9},
  pages = {2511--2520},
  doi = {10.1093/ibd/izaf043}
}
Kostenlos starten →